The Renaissance IPO Index rose 2.8% on Monday, and surpassed its all-time high in mid-day trading. The IPO Index is now up 12.9% for the year, outperforming the S&P 500 by 20 points, and the Nasdaq Composite by 10 points. The...read more
The Hijacking of the IPO Market Part 5 Are IPOs Obsolete? The US IPO is a time-tested process of financial review, disclosure, marketing to investors, evaluation by investors and price discovery....read more
In the second week after the SEC opened we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP),...read more
Renaissance Capital has updated the 2018 US IPO Annual Review with returns through December 31. Download a free Preview of the report, and sign up for IPO market updates delivered to your...read more
IPO Index touches all-time high, fueled by #4 holding Moderna
The Renaissance IPO Index rose 2.8% on Monday, and surpassed its all-time high in mid-day trading. The IPO Index is now up 12.9% for the year, outperforming the S&P 500 by 20 points, and the Nasdaq Composite by 10 points. The...read more
Why Direct Listings Are Fake IPOs
The Hijacking of the IPO Market Part 5 Are IPOs Obsolete? The US IPO is a time-tested process of financial review, disclosure, marketing to investors, evaluation by investors and price discovery....read more
US IPO Weekly Recap: Two billion-dollar biotechs cap a mixed week for biotech IPOs
In the second week after the SEC opened we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP),...read more
Renaissance Capital's Updated 2018 US IPO Annual Review
Renaissance Capital has updated the 2018 US IPO Annual Review with returns through December 31. Download a free Preview of the report, and sign up for IPO market updates delivered to your...read more